Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of treatments for people with advanced liver cancer that has spread. The therapy uses a virus to attack the tumor and drugs to boost the immune system, which may help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have been diagnosed with advanced liver cancer (stage C) and have not had certain prior treatments.
- Your liver function is good enough (Child-Pugh score A or B).
- You are generally well (able to do light activities) and have at least 3 months to live.
- You can swallow pills and have no serious bleeding or heart issues.
- You must not be pregnant or breastfeeding and must use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests combining a special virus injected directly into the tumor with two approved drugs (tislelizumab and lenvatinib) for advanced liver cancer that hasn't been treated before. The goal is to see if this triple approach can shrink tumors and improve outcomes.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.